Ethinylestradiol/gestodene triphasic

Drug Profile

Ethinylestradiol/gestodene triphasic

Alternative Names: Gestodene/ethinylestadiol triphasic; Milvane; Phaeva; Tri Femoden; Tri Gynera; Tri-Minulet; Triadene; Trigynera; Trigynovin; Triminulet; Triminulet 28; Triodeen; Trioden ED; Triodena; Triodene

Latest Information Update: 09 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Akromed; Bayer HealthCare Pharmaceuticals; Wyeth
  • Class Alkylated estrogenic steroids; Norpregnatrienes; Norpregnenes
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Pregnancy

Most Recent Events

  • 09 Feb 2015 Launched for Contraception/Pregnancy (Prevention) in Denmark, Poland and Hungary (PO) prior to February 2015
  • 16 Oct 2009 Wyeth has been acquired by Pfizer
  • 29 Dec 2006 Schering AG is now called Bayer Schering Pharma AG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top